The cardiorenal effects of chronic phosphodiesterase-v inhibition in preclinical diastolic dysfunction (stage b heart failure)
To determine if chronic phosphodiesterase-V (PDEV) inhibition with tadalafil will improve urinary sodium excretion, glomerular filtration rate (GFR), plasma cGMP and urinary cGMP excretion in response to volume expansion (VE) in patients with preclinical diastolic dysfunction (PDD) or stage B heart failure. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 6, 2023 Category: Cardiology Authors: Shravya Vinnakota, Fadi W Adel, Paul M McKie, Christopher G Scott, Horng H Chen Source Type: research
The Cardiorenal Effects of Chronic Phosphodiesterase-V Inhibition in Preclinical Diastolic Dysfunction (Stage B Heart Failure)
To determine whether chronic phosphodiesterase-V (PDEV) inhibition with tadalafil will improve urinary sodium excretion, glomerular filtration rate (GFR), plasma cyclic guanosine 3 ’, 5’-monophosphate (cGMP), and urinary cGMP excretion in response to volume expansion (VE) in patients with preclinical diastolic dysfunction (PDD) or stage B heart failure. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - June 6, 2023 Category: Cardiology Authors: SHRAVYA VINNAKOTA, FADI W. ADEL, PAUL M. MCKIE, CHRISTOPHER G. SCOTT, HORNG H. CHEN Tags: Brief Report Source Type: research
Effect of phosphodiesterase ‐5 inhibition on SystEmic Right VEntricular size and function – a multi‐center, double‐blind, randomized, placebo‐controlled trial – SERVE
This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 2, 2023 Category: Cardiology Authors: Matthias Greutmann,
Daniel Tobler,
Reto Engel,
Dik Heg,
Christian Mueller,
Andr é Frenk,
Harald Gabriel,
Tobias Rutz,
Ronny R. Buechel,
Matthias Willhelm,
Lukas Trachsel,
Michael Freese,
Francisco Javier Ruperti‐Repilado,
Emanuela Valsangi Tags: Research Article Source Type: research
RWD102 Cluster Algorithm for Credible Subgroup Identification in Patients with Erectile Dysfunction Receiving Tadalafil: A Real-World Data Study
This non-comparative, retrospective study aimed to characterize the profiles of erectile disfunction (ED) patients prescribed with tadalafil by clustering the homogenous subpopulations with different ED presentations and risks. (Source: Value in Health)
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: K.T McVary, C. Daluwatte, R.A Kloner, M. Montmerle, M. Rollot, P. Guilmin, M. Blanchon, N. Lambertl, C. Esnault, A. Stewart, T. McGraw Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
CONCLUSION: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don't have any contraindications.PMID:37245088 | DOI:10.22037/uj.v20i.7593 (Source: Urology Journal)
Source: Urology Journal - May 28, 2023 Category: Urology & Nephrology Authors: Mazyar Zahir Mohammad Samzadeh Amirhossien Poopak Ali Reza Khoshdel Arash Armin Source Type: research